Clinical trial · Interventional
Fish Oil Supplementation in Gastrointestinal Cancer
Gastrointestinal Cancer: Effects of the Fish Oil Intake on Nutritional Status, Quality of Life and Immune and Metabolic Outcomes
NCT02699047CI-TRIAL-00022787unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Double-blind, randomized clinical trial to assess the effects of 1,55 g/day of n-3 fatty acids from fish oil concomitant chemotherapy in gastrointestinal cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
| Stomach Cancer | Malignant Gastric Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Encapsulated Olive oil | Dietary Supplement | — | UNRESOLVED |
| Encapsuled fish oil | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Fish oil
- description
- 3.6 g/day of the encapsulated fish oil (2 capsules/day) providing 1.55 g/d of the n-3 polyunsaturated fatty acids (EPA and DHA) during 9 weeks
- interventionNames
- Dietary Supplement: Encapsuled fish oil
- type
- PLACEBO_COMPARATOR
- label
- Control group
- description
- 3.2 g/day of the olive oil (2 capsules/day) without n-3 polyunsaturated fatty acids
- interventionNames
- Dietary Supplement: Encapsulated Olive oil
Primary outcomes (19)
- measure
- Change in Quality of life
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Individuals with age between 18 to 70 y. * Histopathological diagnosis of gastric cancer, or colorectal or anal canal or intestinal cancer * Ability to start chemotherapy in institution (CEPON) * Performance status \<= 2 Exclusion Criteria: * Prior chemotherapy * Inability to oral intake * diagnosis of infectious or inflammatory disease or diabetes * Allergy to fish and / or derivatives, * Pregnant, * Treatment with statins or anti-inflammatories drugs * Intake of fish oil and/or another supplement containing omega-3 or other polyunsaturated fatty acid in the six months prior their inclusion in the study * Continued use of supplements containing antioxidants * Patients in palliative care * without cognitive ability to perform the study protocol * Enrolled in studies with new drugs * Hospitalized patients at recruitment
References
Publications (1)
- DERIVEDCamargo CQ, Mocellin MC, Brunetta HS, Chagas TR, Fabre MES, Trindade EBSM, Silva ELD, Nunes EA. Fish oil decreases the severity of treatment-related adverse events in gastrointestinal cancer patients undergoing chemotherapy: A randomized, placebo-controlled, triple-blind clinical trial. Clin Nutr ESPEN. 2019 Jun;31:61-70. doi: 10.1016/j.clnesp.2019.02.015. Epub 2019 Mar 14. PMID 31060836